FINNENCE ▪ THE WIRE FILE
THE WIRE · № 58574
SEC Filing■ Unclear/unknown
META filed 4 on 2026-09-30
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 00:00 UTC
LAST UPDATE2026-09-30 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions, which can signal insider sentiment but often reflects routine compensation or scheduled sales.
Routine insider filing with no disclosed transaction detail
CATALYST TO WATCH
Follow-up Form 4 detail or insider buying pattern
MAIN RISK
Could be routine vesting or sale, not conviction
FULL DISPATCH
META (CIK 0001564475) filed a 4 on 2026-09-30.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTMeta Platforms · META
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
New Phase 3 trial: Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) — Endo USA Inc., a Keenova Therapeutics Company2026-09-29 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.2026-09-29 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.